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Abstract
Background: DNA methylation changes occurring in cancer cells are featured with both promoter CpG island
hypermethylation and diffuse genomic hypomethylation. Long interspersed element-1 (LINE-1) is repeated in an
interspersed manner with an estimated 500,000 copies per genome. LINE-1 has its CpG sites of the 5′ untranslated
region methylated heavily in normal cells and undergoes demethylation in association with cancerization. However,
little information is available regarding LINE-1 hypomethylation and its prognostic implication in intrahepatic
cholangiocarcinomas.
Methods: A total of 172 cases of intrahepatic cholangiocarcinomas were analyzed for their methylation levels
at four CpG sites of LINE-1 using bisulfite pyrosequencing. We examined the relation between tumoral LINE-1
methylation level and clinicopathological features, including survival.
Results: Tumor differentiation, lymphatic invasion, and T stage were associated with a low average methylation level
of LINE-1 at the four CpG sites; LINE-1 methylation level tended to be lower in high-grade differentiation, lymphatic
emboli, and higher T stage. LINE-1 hypomethylation was significantly linked with lower cancer-specific survival
in patients with intrahepatic cholangiocarcinoma and was found to be an independent prognostic parameter.
Conclusions: Our findings suggest that tumoral LINE-1 hypomethylation could be a molecular biomarker
heralding poor prognosis of patients with intrahepatic cholangiocarcinoma. Our findings need to be validated
in further study.
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Background
DNA methylation changes occurring in cancer cells are
featured with regional promoter CpG island hyperme-
thylation and generalized genomic hypomethylation.
Promoter CpG island hypermethylation contributes to
inactivation of tumor suppressor genes or tumor-related
genes, whereas diffuse genomic hypomethylation is asso-
ciated with chromosomal instability [1]. Repetitive DNA
elements comprise approximately half of the human
genome, and Long interspersed element-1 (LINE-1)
retrotransposons comprise approximately 18% of the
human genome [2]. The 5′ untranslated region sequence
of LINE-1 has a high density of CpG dinucleotides,
which are heavily methylated in normal cells but
undergo hypomethylation in most tissue types of human
cancer, including colorectal cancer [3, 4]. Since the study
by Weisenberger et al. demonstrated a close correlation
between genomic DNA methylation levels, determined
by high-performance liquid chromatography, and LINE-
1 DNA methylation levels determined by PCR-based
measurement [5], LINE-1 methylation levels assessed by
PCR-based methylation assays have been considered a
surrogate marker for genomic methylation levels.
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Intrahepatic cholangiocarcinoma (ICC) is the second
most common primary liver cancer that arises from any
portion of the intrahepatic biliary tree. ICC is a fatal dis-
ease because of its detection at a late stage in its course,
frequent lymphovascular or perineural invasion, and lack
of effective therapeutic modalities [6, 7]. Cancer staging
and subsequent allocation to the optimal treatment
approach is crucial for ICCs. However, none of the existing
staging systems, including the 7th version of the American
Joint Cancer Committee/Union for International Cancer
Control (AJCC/UICC) staging system, fulfills the criteria
for an optimal staging system [8]. The current version of
the AJCC/UICC tumor, lymph node, metastasis (TNM)
staging system for ICCs has been controversial for its pre-
dictive power of prognosis [9, 10] because a recent study
by the Japanese Liver Cancer Study Group demonstrated
no difference in overall survival between TNM stage II and
III ICCs [10]. Although more work should be done to
optimize the existing staging systems, molecular bio-
markers associated with clinical outcome can help to
predict tumor behavior and clinical outcome and
need to be developed.
Studies have demonstrated that tumoral LINE-1 hypo-
methylation is associated with dismal clinical outcome of
patients in many tissue types of human cancer, including
colon cancer and gastric cancer [11–16]. Furthermore, an
independent association of tumoral LINE-1 hypomethyla-
tion with poor prognosis of cancer patients has been dem-
onstrated in the colon, stomach, esophagus, liver, lung,
and brain [13, 16–19]. In the literature, however, no infor-
mation is available regarding the prognostic implications
of LINE-1 methylation status in ICCs. In the present
study, we analyzed levels of LINE-1 methylation in ICC
specimens using bisulfite pyrosequencing and examined
whether LINE-1 methylation status was correlated with
clinicopathological features including survival.
Methods
Patients
A total of 172 formalin-fixed archival tissue samples
were obtained from patients who underwent surgical
resection for ICC at the Seoul National University Hos-
pital, Seoul, South Korea, from April 2005 to December
2012. Fifteen non-neoplastic gallbladder tissue samples
were obtained from patients with chronic cholecystitis.
Hilar cholangiocarcinomas, which arise from the left and
right hepatic ducts at or near their junctions, were ex-
cluded from the study. Through meticulous histological
examinations, combined hepatocellular carcinoma and
cholangiocarcinoma were excluded from the study. The
type of operative procedures included sectionectomy or
segmentectomy in 46 patients (26.7%), lobectomy in 124
(72.1%), and total hepatectomy in 2 (1.2%). Among 172
patients, 6 (3.5%) received neoadjuvant chemotherapy
and 47 (27.3%) received adjuvant chemotherapy and/or
radiotherapy. Thirty-four (19.8%) patients received ad-
juvant chemotherapy and 13 (7.6%) patients received
concurrent chemoradiation therapy after surgery. All
cases were reviewed by experienced gastrointestinal
pathologists (KBL and JJJ) to confirm the diagnosis of
ICC and to re-evaluate histological findings and tumor-
node-metastasis (TNM) stages according to the 4th edi-
tion 2010 WHO classification and the 7th edition 2009
AJCC/UICC staging system, respectively [20, 21]. Gross
types of ICC were classified into three types according to
gross appearance, including mass-forming (MF) type, peri-
ductal infiltrative (PI) type, and intraductal growth (IG)
type [22, 23]. When more than one type was found in a
tumor, the tumor was classified as mixed type. This retro-
spective study was approved by the Institutional Review
Board at the Seoul National University Hospital (IRB No.
H-1011-046-339).
DNA extraction and bisulfite modification
Through microscopic examination, tumor areas in which
1) the tumor cells comprised >45% of total neoplastic
and non-neoplastic cells and 2) represented the predom-
inant histological type of the individual case were
marked with a marker pen. For cases with ICC of mixed
gross type, tumor areas with highest tumor density were
marked in the individual cases. The corresponding areas
were scraped from unstained tissue glass slides with a
knife blade. Because epithelial cells are usually denuded
in normal intrahepatic bile ducts of the formalin-fixed
surgical specimens, cystic ducts of cholecystectomy
specimens were taken as surrogates for normal controls.
Cystic duct epithelia were scraped from the unstained
tissue glass slides and collected into microtubes contain-
ing 50 μL of tissue lysis buffer and proteinase K. After
incubation of the tubes for 48 h at 55 °C, the lysates
were subjected to heating at 95 °C for 30 min. This
prolonged heating was found to be necessary for lessen-
ing the formalin fixation-induced discrepancy in the
measured value of LINE-1 methylation level [24]. With
fixation of tissue samples in formalin solution, formalde-
hyde induces protein-DNA crosslinks and interstrand
DNA crosslinks which may cause some difficulty in ther-
mal and alkaline denaturation. Incomplete denaturation
of double-stranded DNA results in potential under-
conversion of non-methylated cytosines to uracils during
bisulfite treatment, which might cause misleading results
in the measured values of LINE-1 methylation for
formalin-fixed tissue samples. In a previous study, we
found that formalin fixation causes artificial increases in
the measured value of LINE-1 methylation level, and
that prolonged heat-treatment of DNA samples obtained
from formalin-fixed tissue samples decreased the dis-
crepancy in the measured values of LINE-1 methylation
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level between paired fresh-frozen and formalin-fixed
tissue samples [24]. Following centrifugation of the tis-
sue lysates, the supernatants were transferred into new
tubes. DNA samples were subjected to bisulfite modifi-
cation of DNA samples using the EZ DNA methylation
kit (Zymo Research, Orange, CA, USA). LINE-1 methy-
lation levels were measured using PCR pyrosequencing
assay. The primers and PCR conditions were described
previously [12]. The methylation level at each CpG site
was the percentage of C nucleotides relative to the sum
of C and T nucleotides at each CpG site. The four per-
centage values in the four serial CpG sites (nucleotide
positions 328, 321, 318, and 306 of X58075 (GenBank))
were averaged and this mean value was taken as the
overall LINE-1 methylation level in a given sample.
Statistical analysis
Because LINE-1 methylation data followed a normal distri-
bution, we used parametric tests to compare groups. How-
ever, when the following criteria were not met, we used
both parametric tests and non-parametric tests: when two
or more groups were compared, each group n should be
greater than 15. Parametric tests (student t-test and
ANOVA) were performed for comparison of two groups
and three or more groups, respectively. Non-parametric
tests (Mann-Whitney test and Kruskal-Wallis test) were
further performed for the comparison of two groups and
three or more groups, respectively, when one group was
not greater than 15. The cancer-specific survival was calcu-
lated as the time from the date of surgery to the date of
death by ICC. The data from patients who did not experi-
ence cancer-specific death were censored at the last
follow-up visit to obtain the cancer-specific survival. The
Kaplan-Meier log rank test and Cox proportional hazard
method were used for survival analysis. For multivariate
analysis, variables that were found to be significant in uni-
variate analysis were included in the Cox proportional haz-
ard model, and statistically significant variables were then
selected by backward elimination. All p values were two-
sided, and the statistical significance was set at p < 0.05.
SPSS software (IBM SPSS Statistics version 23; Chicago,
IL, USA) was used for all statistical analyses.
Results
Demographic and clinicopathological data
In total, 172 ICC patients underwent hepatic resection be-
tween 2005 and 2012. Of these patients, 147 patients
(85.5%) presented with a single tumor. The male to female
ratio was 121:51, and average age was 62.7 years (median,
63 years; range, 38–80 years). Gross type was MF type in
141 patients, PI type in 8 patients, IG type in 18 patients,
and MF plus PI type in 5 patients. Stage grouping was
stage I in 40, stage II in 37, stage III in 30, and stage IV in
65. Grading was well differentiated in 23, moderately
differentiated in 94, and poorly differentiated in 55. Demo-
graphic and clinicopathological findings are summarized
in Table 1.
Relationship between LINE-1 methylation level and
clinicopathological features
The LINE-1 methylation level was significantly lower in
ICC tissue samples than in normal gallbladder tissue sam-
ples (Fig. 1). Tumoral LINE-1 methylation levels were not
different in ICCs between male and female patients and
between younger and older patients (<64 years old and
≥64 years). No association was found between tumoral
LINE-1 methylation levels and gross types. Tumoral LINE-
1 methylation levels were not different between ICCs of
single-tumor and multiple-tumor types. However, a signifi-
cant difference was noted between well-differentiated ICCs
and moderately or poorly-differentiated ICCs: well-
differentiated ICCs showed higher methylation levels than
those of moderately or poorly differentiated ICCs. Tumoral
LINE-1 methylation levels tended to be higher in T1 stage
than in T2b or higher T stages. No difference in LINE-1
methylation levels was found between ICCs of N0 and N1,
or between ICCs of M0 and M1. While LINE-1 methyla-
tion levels were significantly lower in ICCs with lymphatic
tumor emboli than in ICCs without lymphatic tumor em-
boli, no significant difference was noted between ICCs with
and without venous tumor emboli and between ICCs with
and without perineural invasion.
Relationship between tumoral LINE-1 methylation status
and cancer-specific survival of patients with ICC
When ICCs were grouped into four quadrants (Q1, Q2,
Q3, and Q4 in order of increasing level of LINE-1 methy-
lation) based on their tumoral LINE-1 methylation levels,
Q1 and Q2 exhibited significantly lower cancer-specific
survival than that of Q3 and Q4 (Fig. 2). As displayed in
the Kaplan-Meier survival curve, cancer-specific survival
curves of Q1 and Q2 are similar, while cancer-specific sur-
vival curves of Q3 and Q4 are similar. Thus, ICCs were
further grouped into low methylation status subgroup (Q1
and Q2) and high methylation subgroup (Q3 and Q4).
Low LINE-1 methylation status was associated with worse
cancer-specific survival in Kaplan-Meier survival analysis.
In addition to low LINE-1 methylation status, T staging, N
staging, lymphatic emboli, perineural invasion, and histo-
logical differentiation were included into a multivariate
analysis which revealed that a low LINE-1 methylation
status was independently associated with worse cancer-
specific survival in patients with ICC (Tables 2 and 3).
Discussion
Relationships between low tumoral LINE-1 methylation
status and poor survival have been demonstrated in sev-
eral types of gastrointestinal tract malignancies, including
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esophageal squamous cell carcinoma, gastric adenocarcin-
oma, and colorectal adenocarcinoma. However, no study
is available regarding the relationship between tumoral
LINE-1 hypomethylation and survival of patients with
ICC. In the present study, we have for the first time dem-
onstrated a close association between low tumoral LINE-1
methylation status and poor survival of patients with ICC.
In our previous study, levels of LINE-1 methylation were
demonstrated to be lower in extrahepatic cholangiocarci-
nomas (ECCs) than in normal bile ducts, and the timing
of tumoral LINE-1 hypomethylation is a late event during
multistep carcinogenesis of ECC [25]. However, our
previous study did not analyze the relationship be-
tween tumoral LINE-1 methylation status and survival
of patients with ECC. In the present study, findings
indicate that tumoral LINE-1 hypomethylation might
be an independent parameter heralding poor progno-
sis in patients with ICC.
Many tissue types of human cancer have demon-
strated close associations between tumoral LINE-1 hy-
pomethylation and poor prognosis of patients with the
specific tissue type of cancer. However, no satisfactory
explanation has been provided regarding the reason
why tumoral LINE-1 hypomethylation status contrib-
utes to the aggressive behavior of the tumor, which is
the same case in ICCs. Several speculations might be
made regarding the mechanism by which tumoral
LINE-1 hypomethylation contributes to poor survival
in patients with ICC. Decreased methylation level of
LINE-1 might lead to increased genomic instability
through enhanced non-homologous recombination and
subsequent chromosomal instability, increased retro-
transposon activity and subsequent random insertional
mutation, or decreased mRNA expression of genes har-
boring anti-directional LINE-1 s in their intron sequences.
Such an enhanced genomic instability might cause an
increased expression of proto-oncogenes or a decreased
expression of tumor-suppression genes, which might
Table 1 Relationship between LINE-1 methylation level and
clinicopathological parameters
No. Average SD P-value
Sex
M 121 75.48 7.173 0.233
F 51 76.97 8.216
Age
<64 years 87 75.97 8.274 0.936
≥64 years 85 75.87 6.674
Gross type
Mass forming 141 75.66 7.616 0.702 (ANOVA)
Periductal infiltrative 8 78.62 3.790 0.558 (KW)
Intraductal growth 18 76.73 7.110
Mixed 5 76.16 10.837
Multiplicity
single 147 75.73 7.898 0.422
multiple 25 77.04 4.501
T stage
pT1 48 78.08 6.972 0.049 (ANOVA)
pT2a 38 73.08 9.417 0.012 (KW)
pT2b 14 76.12 4.010
pT3 47 76.04 7.026
pT4 25 75.74 6.622
N stage
pN0 133 75.96 7.861 0.899
pN1 39 75.78 6.223
M stage
pM0 161 76.17 7.593 0.095
pM1 11 72.26 4.972 0.035 (MWa)
TNM stage
I 40 77.81 7.579 0.229
II 37 74.42 8.747
III 30 76.25 7.801
IV 65 75.45 6.406
Differentiation
Well 23 79.69 4.766 0.014
Moderate 94 75.95 6.857
Poorly 55 74.28 8.906
Neural invasion
Absent 118 75.77 8.146 0.701
Present 54 76.25 5.921
Lymphatic invasion
Absent 102 76.92 7.200 0.034
Present 70 74.46 7.749
Table 1 Relationship between LINE-1 methylation level and
clinicopathological parameters (Continued)
Vascular invasion
Absent 95 76.44 8.141 0.396
Present 77 75.27 6.631 0.047 (MWa)
Chronic liver disease
Absent 130 75.95 7.497 0.936
Present 42 75.84 7.617
Chronic biliary disease
Absent 159 75.93 7.679 0.962
Present 13 75.82 5.108
aMann-Whitney
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contribute to increased aggressiveness of ICCs. How-
ever, the exact mechanism by which tumoral LINE-1
hypomethylation contributes to the aggressive behav-
ior is unknown.
TNM system is used to stage ICCs, and staging helps
to guide treatment decisions. However, the prognostic
power of the current version TNM staging system for
ICCs is dubious because in a recent study, overall sur-
vival was not different between stage II and III ICCs
[10]. Because of the weak discriminating power of the
current TNM staging system, it is necessary to develop
molecular markers that can predict tumor behavior
and help to predict the risk of recurrence after the
surgery, in order to plan more effective cancer treat-
ments. In a recent next-generation sequencing-based
study, a clustering analysis of global gene expression
levels was shown to predict prognosis of patients with
biliary tract cancer [26]. The clustering by gene ex-
pression signature was associated with the distribution
of driver gene alterations. ICCs belonging to a cluster
with a high frequency of mutations in BAP1, IDH1,
or NRAS tended to exhibit better clinical outcomes
compared with ICCs belonging to two clusters with a high
frequency of mutations in TP53, KRAS, or SMAD4. How-
ever, the clustering analysis of global gene expression
levels should be validated in an independent study for its
usefulness for prediction of prognosis. In the literature,
however, no single molecular markers, except for immu-
nohistochemical markers, have been demonstrated to be
closely associated with clinical outcome of patients with
Fig. 1 LINE-1 methylation level was significantly lower in tumor tissues of intrahepatic cholangiocarcinoma (n = 15) than in cystic duct epithelia
of non-neoplastic gallbladder (n = 15) (student t-test, p-value <0.001)
Fig. 2 Kaplan-Meier survival analysis with log rank test. ICC patients were grouped into 4 quadrants according to their tumoral LINE-1 methylation
levels. Q1, 2, 3, and 4 are ordered by increasing methylation level of LINE-1. Cancer-specific survival was lower in patients with Q1 or Q2 ICC than
in patients with Q3 or Q4 ICC (a). When ICC patients were grouped into low LINE-1 methylation status (Q1 and 2) and high LINE-1 methylation status
(Q3 and 4,), Cancer-specific survival was significantly lower in the low methylation status group than in the high methylation status group (b)
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ICC. Our findings indicated that tumoral LINE-1 hypome-
thylation status was closely associated with poor prognosis
in patients with ICC and that tumoral LINE-1
hypomethylation was an independent biomarker heralding
poor prognosis in patients with ICC. However, this finding
should be validated in an independent set of ICCs.
Table 2 Univariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival
Parameters Hazard ratio (95% C.I.) P-value
LINE-1 methylation status 0.017
Q4 (n = 43) Reference
Q3 (n = 43) 1.575 (0.561–4.602) 0.320
Q2 (n = 43) 3.369 (1.328–8.551) 0.011
Q1 (n = 43) 3.400 (1.349–8.570) 0.009
LINE-1 methylation status Q3, Q4 (n = 86)
Q1, Q2 (n = 86) 2.643 (1.443–4.482) 0.002
pTNM staging 0.145
I (n = 43) Reference
II (n = 38) 1.636 (0.739–3.622) 0.224
III (n = 30) 0.543 (0.173–1.709) 0.297
IV (n = 61) 1.602 (0.768–3.342) 0.209
T staging 0.044
pT1 (n = 48) Reference
pT2a (n = 38) 1.809 (0.866–3.777) 0.114
pT2b (n = 14) 2.344 (0.929–5.913) 0.071
pT3 (n = 47) 0.941 (0.420–2.107) 0.883
pT4 (n = 25) 0.433 (0.123–1.524) 0.192
N staging pN0 (n = 133)
pN1 (n = 39) 2.328 (1.304–4.157) 0.004
M staging pM0 (n = 161)
pM1 (n = 11) 1.482 (0.533–4.118) 0.451
Gross type 0.076
Mass forming (n = 141) Reference
Periductal infiltrative (n = 8) 0 0.964
Intraductal growth (n = 18) 0.134 (0.018–0.971) 0.047
Mixed (n = 5) 2.672 (0.827–8.638) 0.101
Lymphatic emboli Absent (n = 102)
Present (n = 70) 2.519 (1.429–4.438) 0.001
Vascular invasion Absent (n = 95)
Present (n = 77) 1.111 (0.634–1.945) 0.714
Perineural invasion Absent (n = 118)
Present (n = 54) 0.386 (0.181–0.822) 0.014
Tumor border Expanding (n = 32)
Infiltrative (n = 140) 2.133 (0.846–5.375) 0.108
Tumor differentiation 0.083
Well (n = 23) Reference
Moderate (n = 94) 9.405 (1.283–68.943) 0.027
Poor (n = 55) 9.671 (1.290–72.518) 0.027
Chemotherapy and/or radiotherapy No (n = 120)
Yes (n = 52) 0.979 (0.534–1.792) 0.944
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Because the present study did not perform laser cap-
ture microdissection, a concern may well be raised over
whether variable amounts of immune and stromal cells
contained in the dissected tumor areas may affect the
analysis of LINE-1 methylation level in ICC tumor sam-
ples. After we estimated the ratio of non-neoplastic cells
in tumor areas which were marked for manual dissec-
tion, we analyzed the relationship between LINE-1
methylation level and stroma ratio of tumor area and
found no significant correlation between them (Pearson
correlation coefficient, 0.098 (p-value = 0.199); Spear-
man correlation coefficient, 0.103 (p-value = 0.178)) (see
Additional file 1). For comparison of means, four subsets
of ICCs according to percentage of non-neoplastic cells
(<10%, 10–19%, 20–30%, >30%) were compared regard-
ing the distribution of LINE-1 methylation level and no
significant difference was seen in LINE-1 methylation
level between the subsets (p-value by Kruskal-Wallis
method, 0.242; p-value by ANOVA test, 0.527). For sur-
vival analysis, we grouped ICC cases into two subsets
according to stroma cell ratio (≤15% (n = 90), and, >15%
(n = 82)) and then evaluated prognostic potential of low
methylation status of LINE-1 in each subsets. Regardless
of stroma ratio status, prognostic significance of low
methylation status of LINE-1 was seen in patients with
ICC (see Additional file 2).
In the present study, because of the association
between tumoral LINE-1 methylation level and lymphatic
emboli, both of which were independent prognostic pa-
rameters in ICCs, we expected to develop combinatory
markers that are superior in prognostic power to each
alone. For this aim, ICCs were divided into two groups
(ICCs with lymphatic emboli vs. without lymphatic em-
boli) according to lymphatic emboli. Then, multivariate
analysis was performed in patients with ICCs to elucidate
whether a combination of both parameters, LINE-1
methylation and lymphatic embolus statuses, would
contribute to identification of a subgroup of ICCs
with poor prognosis. Compared with ICCs with high
tumoral LINE-1 methylation status and no lymphatic
tumor emboli, ICCs with low tumoral LINE-1 methy-
lation status and lymphatic tumor emboli showed a
hazard ratio of 3.609 (1.639–7.945), whereas ICCs
with low tumoral LINE-1 methylation status and no
lymphatic tumor emboli harbored a hazard ratio of
0.858 (0.303–2.430) (Table 4).
Table 3 Multivariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival
Hazard ratio (95% C.I.) P-value Hazard ratio (95% C.I.) P-value
LINE-1 methylation levela Q3, Q4 (n = 86)
Q1, Q2 (n = 86) 2.643 (1.443–4.482) 0.002 2.248 (1.205–4.196) 0.011
N staging pN0 (n = 133)
pN1 (n = 39) 2.211 (1.176–4.157) 0.014 2.749 (1.491–5.066) 0.001
T staging 0.025 0.130
pT1 (n = 48) Reference Reference
pT2 (n = 52) 1.943 (0.979–3.855) 0.058 0.555 (0.211–1.458) 0.232
pT3 (n = 47) 0.941 (0.420–2.105) 0.882 0.363 (0.121–1.091) 0.071
pT4 (n = 25) 0.433 (0.123–1.523) 0.192 0.216 (0.053–0.889) 0.034
Gross type 0.076 0.064
Mass forming (n = 141) Reference Reference
Periductal infiltrative (n = 8) 0 0.964 0 0.972
Intraductal growth (n = 18) 0.134 (0.018–0.971) 0.047 0.123 (0.017–0.910) 0.040
Mixed (n = 5) 2.672 (0.827–8.638) 0.101 2.878 (0.854–9.694) 0.088
Lymphatic emboli Absent (n = 102)
Present (n = 70) 2.519 (1.429–4.438) 0.001 2.720 (1.168–6.337) 0.020
Perineural invasion Absent (n = 118)
Present (n = 54) 0.386 (0.181–0.822) 0.014 0.373 (0.162–0.860) 0.021
Differentiation 0.083 0.638
Well (n = 23) Reference
Moderate (n = 94) 9.405 (1.283–68.943) 0.027
Poor (n = 55) 9.671 (1.290–72.518) 0.027
aRegardless of whether adjuvant and/or neoadjuvant therapy was included or not in the multivariate analysis, the hazard ratio of LINE-1 methylation level did
not change
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Conclusions
In summary, we assessed LINE-1 methylation levels in a
total of 172 cases of ICC using PCR pyrosequencing and
elucidated whether LINE-1 methylation status was corre-
lated with clinicopathological features of ICCs. We found
that tumoral LINE-1 hypomethylation was an independ-
ent prognostic factor of outcomes in ICC patients, herald-
ing decreased survival. Further study is required to
validate our findings of tumoral LINE-1 hypomethylation
as a prognostic marker.
Additional files
Additional file 1: A. Scatter plot of LINE-1 methylation and percentage of
non-neoplastic stroma cells in dissected tumor areas. B. Box plot of LINE-1
methylation by grouping ICCs into 3 subsets according to percentage of
non-neoplastic stroma cells. Analysis of the relationship between LINE-1
methylation level and stroma ratio of tumor area did not show significant
correlation between them. No significant difference was seen in tumoral
LINE-1 methylation level between four subsets of ICCs according to
percentage of non-neoplastic cells (<10%, 10–19%, 20–30%, >30%).
(JPEG 307 kb)
Additional file 2: Cancer-specific survival rates with performance of
tumoral LINE-1 hypomethylation in ICCs with stroma cell ratio of ≤15%
(A) and in ICCs with stroma cell ratio of >15% (B). ICC cases were
grouped into two subsets according to their stroma cell ratio (≤15%
(n = 90), and, >15% (n = 82)) and then evaluated regarding prognostic
potential of low methylation status of LINE-1 in each subset. Prognostic
significance of low methylation status of LINE-1 was seen in two subsets.
(JPEG 232 kb)
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Table 4 Multivariate survival analysis of combinatory LINE-1 methylation level and lymphatic embolus status and clinicopathological
parameters with respect to overall survival
Parameters Hazard ratio (95% C.I.) P-value
LINE-1 methylation /lymphatic emboli status 0.001
High/absent (n = 58) Reference
Low/present (n = 28) 3.128 (1.523–6.424) 0.002
Low/absent (n = 44) 1.113 (0.460–2.695) 0.812
High/present (n = 42) 0.761 (0.237–2.443) 0.647
Gross type 0.073
Mass forming (n = 141) Reference
Periductal infiltrative (n = 8) 0 0.972
Intraductal growth (n = 18) 0.141 (0.019–1.032) 0.054
Mixed (n = 5) 3.013 (0.885–10.254) 0.078
T staging 0.152
pT1 (n = 48) Reference
pT2 (n = 52) 0.579 (0. 220–1.526) 0.270
pT3 (n = 47) 0.371 (0.124–1.114) 0.077
pT4 (n = 25) 0.233 (0.056–0.971) 0.046
N staging pN0 (n = 133)
pN1 (n = 39) 2.456 (1.341–4.497) 0.004
Perineural invasion Absent (n = 118)
Present (n = 54) 0.321 (0.147–0.699) 0.004
Differentiation 0.577
Well (n = 23) Reference
Moderate (n = 94) 3.495 (0.332–36.809) 0.298
Poor (n = 55) 3.493 (0.328–37.217) 0.300
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